Update of randomized trials in recurrent disease

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 61-64

  Pujade Lauraine, E ^a   Alexandre, J ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cancer; Ovarian; Randomized; Relapse; Review

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANFOSFAMIDE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPOTHILONE B; ETIRINOTECAN PEGOL; GEMCITABINE; NINTEDANIB; OLAPARIB; PACLITAXEL; PLACEBO; PLEVITREXED; SARACATINIB; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TRABECTEDIN; TREBANANIB; TREOSULFAN; UNINDEXED DRUG; VELIPARIB; VINTAFOLIDE; VISMODEGIB; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK BENEFIT ANALYSIS; FEMALE; OVARY TUMOR; PATHOLOGY; REVIEW; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857396102     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr518     Document Type: Conference Paper

References (33)

1. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193-1202.
2. Ten Bokkel Huinink W, Lane SR, Ross GA. International Topotecan Study Group.Long-term survival in a phase III, randomised study of topotecan versus paclitaxel advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100-103.
3. Gordon AN, Tonda M, Sun S et al. Doxil Study 30-49 Investigators. Long-termsurvival advantage for women treated with pegylated liposomal doxorubicincompared with topotecan in a phase 3 randomized study of recurrent andrefractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
4. O'Byrne KJ, Bliss P, Graham JD et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc AmSoc Clin Oncol 2002; 21: 203a (Abstr 808).
5. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabinecompared with pegylated liposomal doxorubicin in patients with platinumresistantovarian cancer. J Clin Oncol 2008; 26: 890-896.
6. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrentovarian cancer. J Clin Oncol 25; 19: 2811-2818.
7. Meier W, du Bois A, Reuss A et al. Topotecan versus treosulphan in early recurrent ovarian cancer after primary platinum/paclitaxel chemotherapy. A prospective randomized phase III trial of the AGO Ovarian Cancer Study Group. Int J Gynecol Cancer 2004; 14 (Suppl 1): 2 (Abstr 5).
8. Vergote I, Finkler N, del Campo J et al. ASSIST-1 Study Group. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomaldoxorubicin or topotecan as third-line therapy in patients with platinum-refractoryr -resistnt ovarian cancer. Eur J Cancer 2009; 45: 2324-2332.
9. Bolis G, Parazzini F, Scarfone G et al. Paclitaxel vs epidoxorubicin plus paclitaxelas second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999; 72: 60-64.
10. Torri V, Floriani I, Tinazzi A et al. Randomized trial comparingpaclitaxel + doxorubicin versus paclitaxel as second line therapy foradvanced ovarian cancer patients in early progression after platinum basedchemotherapy. Proc Am Soc Clin Oncol 2000; 19: 381a (Abstr 1506).
11. Buda A, Floriani I, Rossi R et al. Randomised controlled trial comparing singleagent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advancedovarian cancer in early progression after platinum-based chemotherapy: anItalian Collaborative Study from the Mario Negri Institute, Milan, GONO (GruppoOncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. BrJ Cancer 2004; 90: 2112-2117.
12. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecancombinations versus topotecan alone for recurrent ovarian cancer: results ofa phase III study of the North-Eastern German Society of Gynecological OncologyOvarian Cancer Study Group. J Clin Oncol 2008; 26: 3176-3182.
13. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomaldoxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
14. Lortholary A, Largillier R, Weber B et al. Weekly paclitaxel as single agent or incombination with carboplatin or weekly topotecan in patients with resistantovarian cancer: the CARTAXHY randomized phase II trial from GINECO. AnnOncol 2011 May 11 [epub ahead of print] doi:10.1093/annonc/mdr149.
15. CantÛ MG, Buda A, Parma G et al. Randomized controlled trial of single-agentpaclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients withrecurrent ovarian cancer who responded to first-line platinum-based regimens.J Clin Oncol 2002; 20: 1232-1237.
16. Bolis G, Scarfone G, Giardina G et al. Carboplatin alone vs carboplatin plusepidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitiveovarian cancer. Gynecol Oncol 2001; 81: 3-9.
17. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-basedchemotherapy versus conventional platinum-based chemotherapy in women withrelapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099-2106.
18. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial ofcarboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrentadvanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion enCancer de Ovario) study. Ann Oncol 2005; 16: 749-755.
19. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin comparedwith carboplatin in patients with platinum-sensitive recurrent ovarian cancer: anintergroup trial of the AGO-OVAR, the NCIC-CTG, and the EORTC-GCG. J ClinOncol 2006; 24: 4699-4707.
20. Markman M, Moon J, Wilczynski S et al. Single agent carboplatin versuscarboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer:final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol2010; 116: 323-325.
21. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomaldoxorubicin and carboplatin compared with paclitaxel and carboplatin forpatients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol2010; 28: 3323-3329.
22. Aghajanian C, Finkler NJ, Rutherford T. OCEANS: a randomized, double-blinded,placebo-controlled phase III trial of chemotherapy with or without bevacizumab(BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC),primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29(Suppl 15): Abstr LBA 5007.
23. Ledermann J, Hackshaw A, Kaye S et al. Randomized phase II placebo-controlledtrial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011 August 22epub ahead of print].
24. Karlan BY, Oza AM, Hansen VL et al. Randomized, double-blind, placebocontrolledphase II study of AMG 386 combined with weekly paclitaxel in patients(pts) with recurrent ovarian carcinoma. J Clin Oncol 2010; 28: 15s (Abstr 5000).
25. Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: a randomized phase IItrial comparing EC145 and pegylated liposomal doxorubicin (PLD) incombination, versus PLD alone, in subjects with platinum-resistant ovariancancer. J Clin Oncol 2011; 29 (Suppl 15); Abstr 5045.
26. Audeh MW, Penson RT, Friedlander M et al. Phase II trial of the oral PARPinhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J ClinOncol 2009; 27 (Suppl 15); Abstr 5500.
27. Kaye S, Kaufman B, Lubinski J et al. Phase II study of the oral PARP inhibitorolaparib (AZD2281) vs liposomal doxorubicin in ovarian cancer patients withBRCA1 and/or BRCA2 mutations. Ann Oncol 2010; 21 (Suppl 8); viii304-viii313(Abstr 9710).
28. Ledermann JA, Harter P, Gourley C et al. Phase II randomized placebo-controlledstudy of olaparib (AZD2281) in patients with platinum-sensitive relapsed serousovarian cancer (PSR SOC). J Clin Oncol 2011; 29 (Suppl 15); Abstr 5003.
29. Colombo N, Schwartz PE, Bamias A. Results of a randomized, open-label, phase III trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian, orpritoneal cancer. Thirty-fifth European Society for Medical Oncology Congress(Abstr 4843). Milan 2010.
30. Vergote IB, Micha JP, Pippitt CH Jr et al. Phase II study of NKTR-102 in womenwith platinum-resistant/refractory ovarian cancer. J Clin Oncol 2010; 28: 15s(Abstr 5013).
31. Glasspool RM, Gore M, Rustin G et al. Randomized phase II study ofdecitabine in combination with carboplatin compared with carboplatin alonein patients with recurrent advanced ovarian cancer. J Clin Oncol 2009; 27: 15s(Abstr 5562).
32. Fehrenbacher L, Kaye S, Holloway R. A phase 2, randomized, placebo-controlledstudy of Hedgehog (Hh) pathway inhibitor GDC-0449 as maintenance therapy inpatients with ovarian cancer in 2nd or 3rd complete remission (CR). Thirty-fifth European Society for Medical Oncology Congress (LBA 25). Milan 2010.
33. Hurteau JA, Brady MF, Darcy KM et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to firstline platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group study. Gynecol Oncol 2010; 119: 444-450.